Multiantivirus compound, composition and method for treatment of virus diseases
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8420617-B2
Publication Date
2013-04-16
Expiration Date
Abstract
A method for obtaining a new antiviral compound with multiple action against many viruses, comprising modified highly purified yeast RNA, a pharmaceutical composition comprising such RNA, and a method for the treatment and prevention of viral disease comprising administering to a patient a composition comprising an amount effective to ameliorate the symptoms of viral disease of ribonucleic acid. The exogenous modified yeast RNA has a pronounced multiple anti-virus action in a wide range of concentrations. The modified yeast RNA is capable of inhibiting the reproduction of viruses from Orthomyxoviridae, Paramyxovirus, Hepatitis, Herpesviridae families, enterovirus and adenovirus. Also, the modified yeast RNA is capable of inhibiting the reproduction of influenza viruses, hepatitis C virus, genital herpes, human immunodeficiency virus and Coxsackie B virus.
Core Innovation
The invention relates to an antiviral method of preparing a composition for preventing or treating an infection by a virus. The method comprises heating a purified yeast RNA extract with mannitol at a temperature in the range 40-70 °C, and the process yields a composition comprising the purified RNA extract combined with mannitol.
The yeast RNA extract comprises nucleotide fragments having 25-110 nucleotides with a purity degree of at least 99% by weight. In the composition, the yeast RNA extract and mannitol are present in a proportion from about 2:1 to about 3:1 by weight, and the RNA extract constitutes at least about 50% by weight of the composition.
The patent describes modified highly purified yeast RNA combined with a sugar to form a multi-antiviral composition. It asserts novelty in the specific combination and preparation, and describes broad inhibition of viral reproduction across multiple virus families, including Orthomyxoviridae, Paramyxovirus, hepatitis viruses including HCV, Herpesviridae including HSV, enteroviruses including Coxsackie B, and adenovirus.
Claims Coverage
The provided content shows one independent claim directed to a preparation method for an antiviral composition. The inventive coverage centers on three features: the heating step, the purified yeast RNA fragment definition, and the composition proportion with mannitol.
Heating purified yeast RNA extract with mannitol at 40-70 °C
Heating a purified yeast RNA extract with mannitol at a temperature in the range 40-70 °C so as to obtain a composition comprising the purified RNA extract combined with mannitol.
Yeast RNA extract as 25-110 nucleotide fragments at at least 99% by weight purity
The yeast RNA extract comprises nucleotide fragments having 25-110 nucleotides with a purity degree of at least 99% by weight.
Mannitol-to-RNA weight proportion of about 2:1 to about 3:1 with RNA at least about 50% by weight
The yeast RNA extract and mannitol are present in the composition in a proportion of from about 2:1 to about 3:1 by weight, and the RNA extract constitutes at least about 50% by weight of the composition.
The claim coverage centers on preparing an antiviral composition from highly purified yeast RNA fragments and mannitol under a defined heating condition, with specific weight ratios and minimum RNA content.
Stated Advantages
Broad inhibition of viral reproduction across multiple virus families including Orthomyxoviridae, Paramyxovirus, hepatitis viruses including HCV, Herpesviridae including HSV, enteroviruses including Coxsackie B, and adenovirus.
Interference with influenza hemagglutinin/neuraminidase.
Induction of alpha-interferon through innate immune activation.
Documented Applications
Prevention and treatment of viral infections in ARVI/influenza patients, with symptom improvement described versus Tamiflu.
HCV applications including a human study reporting viral load decline and tolerability.
Topical/genital herpes evaluations including trials for genital herpes compared against Virolex.
In vitro and in vivo model evaluations for influenza, HCV, HSV, and other virus families, including reported inhibition of viral replication in tissue culture and animal models.
Interested in licensing this patent?